E2A, VA RNA I, and L4-22k adenoviral helper genes are sufficient for AAV production in HEK293 cells
Molecular Therapy - Methods & Clinical Development · 2024-12 · 32 (4) · 101376
DOI: 10.1016/j.omtm.2024.101376 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy - Methods & Clinical Development, 2024-12. Verfasst von Jiten Doshi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Schepens Eye Research Institute, Mass Eye and Ear Infirmary, Boston, MA, USA. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eli Lilly and Co.
Abstract (Originalsprache)
The replication-defective adeno-associated virus (AAV) is extensively utilized as a research tool or vector for gene therapy. The production process of AAV remains intricate, expensive, and mechanistically underexplored. With the aim of enhancing AAV manufacturing efficiencies in mammalian cells, we revisited the questions and optimization surrounding the requirement of the various adenoviral helper genes in enabling AAV production. First, we refined the minimal set of adenoviral genes in HEK293 AAV production to E2A, L4-22 K /33 K, and VA RNA I. These findings challenge the previously accepted necessity of adenoviral E4orf6 in AAV production. In addition, we identified L4-22 K genes as crucial helpers for AAV production. Next, a revised minimal adenoviral helper plasmid comprising E2A, L4-22 K, and VA RNA I genes was designed and demonstrated to yield high titer and potent AAV preps in HEK293 transient transfection. Lastly, stable packaging cells harboring inducible E2A and L4-22 K genes were shown to maintain AAV production yields comparable to transient transfection over a culture period of ∼10 weeks. Combined, these findings further our understanding of adenoviral helper function in mammalian AAV production and provide novel plasmid and cell-line reagents with an improved safety profile for potential broad applicability in the research and gene therapy community.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Schepens Eye Research Institute, Mass Eye and Ear Infirmary, Boston, MA, USA.
- Harvard Medical School, Boston, MA, USA.
- Broad Institute of MIT and Harvard, Boston, MA, USA.
Förderung
- Eli Lilly and Co
Zitieren
APA
Doshi, J., Couto, E., Staiti, J., Vandenberghe, L. H., & Zabaleta, N. (2024). E2A, VA RNA I, and L4-22k adenoviral helper genes are sufficient for AAV production in HEK293 cells. Molecular Therapy - Methods & Clinical Development, 32(4), 101376. https://doi.org/10.1016/j.omtm.2024.101376
Vancouver
Doshi J, Couto E, Staiti J, Vandenberghe LH, Zabaleta N. E2A, VA RNA I, and L4-22k adenoviral helper genes are sufficient for AAV production in HEK293 cells. Molecular Therapy - Methods & Clinical Development. 2024;32(4):101376. doi:10.1016/j.omtm.2024.101376
BibTeX
@article{Doshi2024,
author = {Doshi, Jiten and Couto, Emma and Staiti, Jillian and Vandenberghe, Luk H and Zabaleta, Nerea},
title = {E2A, VA RNA I, and L4-22k adenoviral helper genes are sufficient for AAV production in HEK293 cells},
journal = {Molecular Therapy - Methods & Clinical Development},
year = {2024},
volume = {32},
number = {4},
pages = {101376},
doi = {10.1016/j.omtm.2024.101376}
}
EUVIMED